Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.
临床用于缓解膀胱过度活动症伴随的急迫性尿失禁、尿急、尿频症状。
Site AU10000, Sydney, Australia
Site KR82001, Seoul, Korea, Republic of
Site KR410008, Daejeon, Korea, Republic of
Site KR410009, Incheon, Korea, Republic of
Site KR410005, Kangam, Korea, Republic of
Samsung Medical Center, Seoul, Korea, Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.